Ignite Creation Date:
2025-12-18 @ 8:23 AM
Ignite Modification Date:
2025-12-23 @ 10:23 PM
Study NCT ID:
NCT07197515
Status:
None
Last Update Posted:
2025-09-29 00:00:00
First Post:
2025-09-03 00:00:00
Is Possible Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Legal Evaluation for Greater Access to Cancer Care (LEGAL-CARE)
Sponsor:
None
Organization:
Study Overview
Official Title:
Legal Evaluation for Greater Access to Cancer Care (LEGAL-CARE): A Pilot Feasibility Trial of a Legal Navigation Program to Address Cancer-related Legal Barriers
Status:
None
Status Verified Date:
2025-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
LEGAL-CARE
Brief Summary:
Despite an adept social and navigation workforce, the regulatory and legal landscape for patients with cancer has become increasingly difficult to navigate. Many barriers faced by patients are entrenched in local, state, and federal policies that require expertise in both social needs and the law. Recently, the investigators led the first nationwide study investigating the extent to which patients with cancer encounter legal barriers related to disability, employment, health insurance, and financial assistance. There is an urgent need for evidence on how interventions can mitigate cancer-related legal barriers and impact care.
The Legal Evaluation for Greater Access to Cancer Care (LEGAL-CARE) is a pilot feasibility trial of a legal navigation program to address cancer-related legal barriers. A small cohort of patients will be offered at least one cycle of legal intervention over a 6-month period. Legal intervention is defined as a legal navigator proactively reaching out to the patient to discuss legal hardship during their treatment. This study will take place in the medical oncology clinics at the O'Neal Comprehensive Cancer Center. Inclusion criteria includes any adult aged 18 or older with a new diagnosis of advanced stage cancer (stages III or IV) requiring systemic therapy that is being seen in clinic. The objectives of this study are to evaluate the feasibility of a legal intervention, and understand patient perceptions utilizing semi-structured interviews. Additionally, it will assess patient-reported financial toxicity, quality of life, and health care utilization between patients receiving legal navigation. The investigators hypothesize this legal intervention would be feasible, acceptable and implemented as intended by the research protocol, while also demonstrating measurable improvement in patient outcomes.
The LEGAL-CARE study is relevant to the investigators' catchment area with a unique legal and regulatory landscape in Alabama, and situated in the context of recent American Society of Clinical Oncology (ASCO)-level and federal-level policy developments examining the role of legal services and SDOH in the context of cancer care. This study is significant as it will be the first to prospectively investigate the impact of legal barriers on patient care. It is innovative for multiple reasons. It employs a unique legal intervention and assesses the feasibility and acceptability of the intervention in preparation for a larger multi-site trial. It leverages a unique partnership between O'Neal's social work service, and the nation's largest organization providing legal assistance to patients with cancer, and community legal aid organizations in Birmingham. Finally, it results in a rich mixed methods analytic dataset that will allow implementation-related information from the intervention to be utilized in an R01 grant to scale this regionally.
The Legal Evaluation for Greater Access to Cancer Care (LEGAL-CARE) is a pilot feasibility trial of a legal navigation program to address cancer-related legal barriers. A small cohort of patients will be offered at least one cycle of legal intervention over a 6-month period. Legal intervention is defined as a legal navigator proactively reaching out to the patient to discuss legal hardship during their treatment. This study will take place in the medical oncology clinics at the O'Neal Comprehensive Cancer Center. Inclusion criteria includes any adult aged 18 or older with a new diagnosis of advanced stage cancer (stages III or IV) requiring systemic therapy that is being seen in clinic. The objectives of this study are to evaluate the feasibility of a legal intervention, and understand patient perceptions utilizing semi-structured interviews. Additionally, it will assess patient-reported financial toxicity, quality of life, and health care utilization between patients receiving legal navigation. The investigators hypothesize this legal intervention would be feasible, acceptable and implemented as intended by the research protocol, while also demonstrating measurable improvement in patient outcomes.
The LEGAL-CARE study is relevant to the investigators' catchment area with a unique legal and regulatory landscape in Alabama, and situated in the context of recent American Society of Clinical Oncology (ASCO)-level and federal-level policy developments examining the role of legal services and SDOH in the context of cancer care. This study is significant as it will be the first to prospectively investigate the impact of legal barriers on patient care. It is innovative for multiple reasons. It employs a unique legal intervention and assesses the feasibility and acceptability of the intervention in preparation for a larger multi-site trial. It leverages a unique partnership between O'Neal's social work service, and the nation's largest organization providing legal assistance to patients with cancer, and community legal aid organizations in Birmingham. Finally, it results in a rich mixed methods analytic dataset that will allow implementation-related information from the intervention to be utilized in an R01 grant to scale this regionally.
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: